Last reviewed · How we verify
Xerava (ERAVACYCLINE)
Xerava works by inhibiting protein synthesis in bacteria, ultimately leading to their death.
Xerava (eravacycline) is a small molecule antibiotic developed by Tetraphase Pharmaceuticals. It is approved to treat complicated intra-abdominal infections and complicated urinary tract infections caused by susceptible bacteria. Xerava was approved by the FDA in 2019 and is currently patented. Key safety considerations include its potential to cause gastrointestinal side effects and the risk of antibiotic resistance. Xerava's commercial status is patented, with no generic manufacturers available.
At a glance
| Generic name | ERAVACYCLINE |
|---|---|
| Sponsor | Tetraphase Pharms |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 2019 |
Mechanism of action
Eravacycline is an antibacterial drug [see Microbiology ( 12.4 )].
Approved indications
- complicated intra-abdominal infections
- complicated urinary tract infections
- infections that are proven or strongly suspected to be caused by susceptible bacteria
- complicated intra-abdominal infections caused by Escherichia coli
- complicated intra-abdominal infections caused by Klebsiella pneumoniae
- complicated intra-abdominal infections caused by Citrobacter freundii
- complicated intra-abdominal infections caused by Enterobacter cloacae
- complicated intra-abdominal infections caused by Klebsiella oxytoca
- complicated intra-abdominal infections caused by Enterococcus faecalis
- complicated intra-abdominal infections caused by Enterococcus faecium
Common side effects
- Infusion site reactions
- Nausea
- Vomiting
- Diarrhea
- Hypotension
- Wound dehiscence
- Palpitations
- Acute pancreatitis
- Pancreatic necrosis
- Chest pain
- Hypersensitivity
- Increased amylase
Drug interactions
- Strong CYP3A Inducers
- Anticoagulant Drugs
Key clinical trials
- Therapeutic Options for CRAB (PHASE4)
- The Efficacy and Adverse Reactions of Neotetracycline in the Treatment of GNB Infections
- A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI) (PHASE2)
- Optimising TREATment for Severe Gram-Negative Bacterial Infections (PHASE4)
- Real-World Pharmacokinetic/Pharmacodynamic Study of Eravacycline in Critically III Patients
- A Study on the Combination Therapy of Eravacycline for Treating Carbapenem-Resistant Acinetobacter Baumannii Pneumonia
- Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia (PHASE2)
- Eravacycline Combination Therapy for MRAB
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xerava CI brief — competitive landscape report
- Xerava updates RSS · CI watch RSS
- Tetraphase Pharms portfolio CI